Maliha Khan1, Jorge Cortes1, Wei Qiao2, Mohanad A Alzubaidi1, Sherry A Pierce1, Farhad Ravandi1, Hagop M Kantarjian1, Gautam Borthakur3. 1. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. 2. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX. 3. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: gborthak@mdanderson.org.
Abstract
PURPOSE: To determine the factors associated with outcomes in patients with core binding factor acute myeloid leukemia (CBF-AML) in first relapse. MATERIAL AND METHODS: We conducted a retrospective analysis of 92 patients with CBF-AML in first relapse who presented to our institution from 1990-2014. Clinical and demographic parameters were included in univariate and multivariate Cox proportional hazards regression model to predict overall survival. RESULTS: Among the 92 relapsed patients, 60 (65%) patients had inv (16) and 32 (35%) had t (8;21). The median survival for patients with inv(16) cytogenetic group was 15.6 months (range 10.32 to 20.88 months) while for the t(8;21) group was 9 months (range 3.68 to 14.32) (P = .004). Univariate Cox model analysis showed that increased age, high white blood cell count, t (8;21) cytogenetic group, and high bone marrow blast percentage were associated with poor overall outcome, while stem cell transplant intervention was associated with better survival. Additional cytogenetic aberrations at relapse were not associated with survival outcomes (P = .4). Multivariate Cox model analysis showed that t(8;21) cytogenetic group has more hazard of death after adjusting, age, marrow blast percentage, blood cell count, and stem cell transplant(hazard ratio 1.802; P = .02). CONCLUSION: Among patients with relapsed CBF-AML, median survival was less than a year and half and the outcome was worse in patients with t (8;21). Despite the relatively better outcomes, dedicated clinical trials are needed to improve the outcome in all patients with relapsed CBF-AML.
PURPOSE: To determine the factors associated with outcomes in patients with core binding factor acute myeloid leukemia (CBF-AML) in first relapse. MATERIAL AND METHODS: We conducted a retrospective analysis of 92 patients with CBF-AML in first relapse who presented to our institution from 1990-2014. Clinical and demographic parameters were included in univariate and multivariate Cox proportional hazards regression model to predict overall survival. RESULTS: Among the 92 relapsed patients, 60 (65%) patients had inv (16) and 32 (35%) had t (8;21). The median survival for patients with inv(16) cytogenetic group was 15.6 months (range 10.32 to 20.88 months) while for the t(8;21) group was 9 months (range 3.68 to 14.32) (P = .004). Univariate Cox model analysis showed that increased age, high white blood cell count, t (8;21) cytogenetic group, and high bone marrow blast percentage were associated with poor overall outcome, while stem cell transplant intervention was associated with better survival. Additional cytogenetic aberrations at relapse were not associated with survival outcomes (P = .4). Multivariate Cox model analysis showed that t(8;21) cytogenetic group has more hazard of death after adjusting, age, marrow blast percentage, blood cell count, and stem cell transplant(hazard ratio 1.802; P = .02). CONCLUSION: Among patients with relapsed CBF-AML, median survival was less than a year and half and the outcome was worse in patients with t (8;21). Despite the relatively better outcomes, dedicated clinical trials are needed to improve the outcome in all patients with relapsed CBF-AML.
Authors: Guido Marcucci; Krzysztof Mrózek; Amy S Ruppert; Kati Maharry; Jonathan E Kolitz; Joseph O Moore; Robert J Mayer; Mark J Pettenati; Bayard L Powell; Colin G Edwards; Lisa J Sterling; James W Vardiman; Charles A Schiffer; Andrew J Carroll; Richard A Larson; Clara D Bloomfield Journal: J Clin Oncol Date: 2005-08-20 Impact factor: 44.544
Authors: Jan J Cornelissen; Wim L J van Putten; Leo F Verdonck; Matthias Theobald; Emanuel Jacky; Simon M G Daenen; Marinus van Marwijk Kooy; Pierre Wijermans; Harry Schouten; Peter C Huijgens; Hans van der Lelie; Martin Fey; Augustin Ferrant; Johan Maertens; Alois Gratwohl; Bob Lowenberg Journal: Blood Date: 2007-01-09 Impact factor: 22.113
Authors: Frederick R Appelbaum; Kenneth J Kopecky; Martin S Tallman; Marilyn L Slovak; Holly M Gundacker; Haesook T Kim; Gordon W Dewald; Hagop M Kantarjian; Sherry R Pierce; Elihu H Estey Journal: Br J Haematol Date: 2006-08-25 Impact factor: 6.998
Authors: Peter Paschka; Guido Marcucci; Amy S Ruppert; Krzysztof Mrózek; Hankui Chen; Rick A Kittles; Tamara Vukosavljevic; Danilo Perrotti; James W Vardiman; Andrew J Carroll; Jonathan E Kolitz; Richard A Larson; Clara D Bloomfield Journal: J Clin Oncol Date: 2006-08-20 Impact factor: 44.544
Authors: Frederick R Appelbaum; Holly Gundacker; David R Head; Marilyn L Slovak; Cheryl L Willman; John E Godwin; Jeanne E Anderson; Stephen H Petersdorf Journal: Blood Date: 2006-02-02 Impact factor: 22.113
Authors: Se Young Han; Krzysztof Mrózek; Jenna Voutsinas; Qian Wu; Elizabeth A Morgan; Hanne Vestergaard; Robert Ohgami; Philip M Kluin; Thomas Kielsgaard Kristensen; Sheeja Pullarkat; Michael Boe Møller; Ana-Iris Schiefer; Linda B Baughn; Young Kim; David Czuchlewski; Jacobien R Hilberink; Hans-Peter Horny; Tracy I George; Michelle Dolan; Nam K Ku; Cecilia Arana Yi; Vinod Pullarkat; Jessica Kohlschmidt; Amandeep Salhotra; Lori Soma; Clara D Bloomfield; Dong Chen; Wolfgang R Sperr; Guido Marcucci; Christina Cho; Cem Akin; Jason Gotlib; Sigurd Broesby-Olsen; Melissa Larson; Michael A Linden; H Joachim Deeg; Gregor Hoermann; Miguel-Angel Perales; Jason L Hornick; Mark R Litzow; Ryotaro Nakamura; Daniel Weisdorf; Gautam Borthakur; Gerwin Huls; Peter Valent; Celalettin Ustun; Cecilia C S Yeung Journal: Blood Adv Date: 2021-05-25